264,523 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Nuveen LLC

Key Points

• Nuveen LLC has acquired 264,523 shares of Tarsus Pharmaceuticals, valued at approximately $13.6 million, representing a 0.63% ownership stake as per their SEC filing.
• The stock of Tarsus Pharmaceuticals has seen a 2.1% increase recently, and it currently trades around $56.56, with a market cap of $2.39 billion.
• Despite missing earnings estimates with a loss of ($0.48) EPS, Tarsus reported revenue of $102.66 million, exceeding expectations of $95.81 million.

Nuveen LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 264,523 shares of the company's stock, valued at approximately $13,589,000. Nuveen LLC owned 0.63% of Tarsus Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TARS. Toronto Dominion Bank acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $105,714,000. Lord Abbett & CO. LLC raised its stake in Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after acquiring an additional 685,111 shares in the last quarter. Millennium Management LLC raised its stake in Tarsus Pharmaceuticals by 189.4% during the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock worth $35,659,000 after acquiring an additional 421,495 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its stake in Tarsus Pharmaceuticals by 5,636.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock worth $22,383,000 after acquiring an additional 397,190 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Tarsus Pharmaceuticals by 92.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 460,773 shares of the company's stock worth $25,514,000 after acquiring an additional 221,458 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Down 1.8%

Shares of TARS stock traded down $1.03 on Wednesday, hitting $57.82. The stock had a trading volume of 354,302 shares, compared to its average volume of 724,928. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -24.82 and a beta of 0.79. The stock's 50 day moving average is $44.87 and its 200-day moving average is $45.94. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. Tarsus Pharmaceuticals, Inc. has a 52-week low of $25.82 and a 52-week high of $58.95.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The company had revenue of $102.66 million for the quarter, compared to the consensus estimate of $95.81 million. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer owned 818,106 shares of the company's stock, valued at $40,905,300. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.97% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TARS has been the topic of several research analyst reports. Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective on the stock. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research note on Tuesday, May 27th. Finally, Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $66.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.